GlassScriptPhysician profile
Kala R Haynes
NPI 1508171315
$3,881.80
in general payments reported to CMS, 2019-2025
20 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $358 · 2023: $922 · 2024: $1,260 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,172 · Education: $70.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,172.02 |
| Education | $70.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $574.02 | 2023-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $523.83 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $442.08 | 2021-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $396.04 | 2021-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $389.65 | 2022-2025 | Acthar |
| Vifor Pharma, INC. | $351.54 | 2021-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $314.63 | 2022-2025 | Tarpeyo |
| Amgen INC. | $248.39 | 2022-2025 | Krystexxa, Tavneos |
| Ardelyx, INC. | $221.14 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Fresenius USA Marketing, INC. | $107.88 | 2024-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.96 | 2024 | Jardiance |
| Lilly USA, LLC | $42.09 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $41.39 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $34.92 | 2023-2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $30.45 | 2025 | Purified Cortrophin Gel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $27.85 | 2022-2024 | Lupkynis |
| Daiichi Sankyo INC. | $24.90 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.83 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.38 | 2021 | |
| Genzyme Corporation | $14.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kala Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.